Drug Insight: nucleoside and nucleotide analog inhibitors for hepatitis B

被引：21

作者：

Fung, Scott K. ^{[1
]}

Lok, Anna S. F. ^{[1
]}

机构：

[1] Univ Michigan, Med Ctr, Div Gastroenterol, Ann Arbor, MI 48109 USA

来源：

NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY | 2004年 / 1卷 / 02期

关键词：

adefovir dipivoxil; antiviral resistance; chronic hepatitis B; lamivudine;

D O I：

10.1038/ncpgasthep0056

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

In the past decade, substantial advances have been made in the treatment of chronic hepatitis B. Approved treatments include interferon-alpha, the nucleoside analog inhibitor lamivudine, and the nucleotide analog inhibitor adefovir dipivoxil. This review provides insights into the benefits and limitations of lamivudine and adefovir dipivoxil for the treatment of chronic hepatitis B. Lamivudine and adefovir dipivoxil have similar antiviral efficacies. Lamivudine has negligible side effects but a high rate of drug resistance, whereas adefovir dipivoxil has a low rate of drug resistance but long-term use is associated with a small risk of nephrotoxicity. Several other nucleoside and nucleotide analogs are being evaluated in phase II/III clinical trials for hepatitis B.

引用

收藏

页码：90 / 97

页数：8

相关论文

共 58 条

[1]

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine [J].

Allen, MI ;

Deslauriers, M ;

Andrews, CW ;

Tipples, GA ;

Walters, KA ;

Tyrrell, DLJ ;

Brown, N ;

Condreay, LD .

HEPATOLOGY, 1998, 27 (06) :1670-1677

[2]

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase [J].

Angus, P ;

Vaughan, R ;

Xiong, S ;

Yang, HL ;

Delaney, W ;

Gibbs, C ;

Brosgart, C ;

Colledge, D ;

Edwards, R ;

Ayres, A ;

Bartholomeusz, A ;

Locarnini, S .

GASTROENTEROLOGY, 2003, 125 (02) :292-297

[3]

Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy [J].

Boni, C ;

Penna, A ;

Ogg, GS ;

Bertoletti, A ;

Pilli, M ;

Cavallo, C ;

Cavalli, A ;

Urbani, S ;

Boehme, R ;

Panebianco, R ;

Fiaccadori, F ;

Ferrari, C .

HEPATOLOGY, 2001, 33 (04) :963-971

[4]

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B [J].

Boni, C ;

Penna, A ;

Bertoletti, A ;

Lamonaca, V ;

Rapti, I ;

Missale, G ;

Pilli, M ;

Urbani, S ;

Cavalli, A ;

Cerioni, S ;

Panebianco, R ;

Jenkins, J ;

Ferrari, C .

JOURNAL OF HEPATOLOGY, 2003, 39 (04) :595-605

[5]

Determinants for sustained HBeAg response to lamivudine therapy [J].

Chien, RN ;

Yeh, CT ;

Tsai, SL ;

Chu, CM ;

Liaw, YF .

HEPATOLOGY, 2003, 38 (05) :1267-1273

[6]

Chien RN, 2002, GASTROENTEROLOGY, V123, P67

[7]

EASL International Concensus Conference on Hepatitis B -: 13-14 September, 2002 Geneva, Switzerland Consensus Statement (Long version) [J].

de Franchis, R ;

Hadengue, A ;

Lau, G ;

Lavanchy, D ;

Lok, A ;

McIntyre, N ;

Mele, A ;

Paumgartner, G ;

Pietrangelo, A ;

Rodés, J ;

Rosenberg, W ;

Valla, D .

JOURNAL OF HEPATOLOGY, 2003, 39 :S3-S25

[8]

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss [J].

de Man, RA ;

Bartholomeusz, AI ;

Niesters, HGM ;

Zondervan, PE ;

Locarnini, SA .

JOURNAL OF HEPATOLOGY, 1998, 29 (04) :669-675

[9]

ANTIVIRAL ACTIVITY SPECTRUM AND TARGET OF ACTION OF DIFFERENT CLASSES OF NUCLEOSIDE ANALOGS [J].

DECLERCQ, E .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 1994, 13 (6-7) :1271-1295

[10]

Durability of serologic response after lamivudine treatment of chronic hepatitis B [J].

Dienstag, JL ;

Cianciara, J ;

Karayalcin, S ;

Kowdley, KV ;

Willems, B ;

Plisek, S ;

Woessner, M ;

Gardner, S ;

Schiff, E .

HEPATOLOGY, 2003, 37 (04) :748-755

← 1 2 3 4 5 6 →